Search results
Results from the WOW.Com Content Network
Lupron injection was approved by the FDA for treatment of advanced prostate cancer on 9 April 1985. [45] [4] [43] [44] Lupron depot for monthly intramuscular injection was approved by the FDA for palliative treatment of advanced prostate cancer on 26 January 1989. [8]
Cyproterone acetate (CPA), sold alone under the brand name Androcur or with ethinylestradiol under the brand names Diane or Diane-35 among others, is an antiandrogen and progestin medication used in the treatment of androgen-dependent conditions such as acne, excessive body hair growth, early puberty, and prostate cancer, as a component of feminizing hormone therapy for transgender individuals ...
His insurer initially covered 100 percent of the cost of the injections. But when the plan changed insurers, he was suddenly faced with $180 in cost-sharing for each one — an amount that he ...
Hook's Drug Stores was an Indianapolis, Indiana–based drug store chain which was founded in 1900 by John A. Hook. The chain flourished throughout central Indiana for most of the 20th-century. Hook's did business under its own banner, the SupeRX Drug Stores banner outside its core market, and the Brooks Pharmacy banner after acquiring the New ...
Drug overdoses in Indiana have nearly doubled since 2010, growing from 923 to 1,809 in 2017. Approximately 4,000 Hoosiers have died from opioids in the last decade. Indiana’s drug-induced ...
Depot injections can be created by modifying the drug molecule itself, as in the case of prodrugs, or by modifying the way it is administered, as in the case of oil/lipid suspensions. Depot injections can have a duration of action of one month or greater and are available for many types of drugs, including antipsychotics and hormones.
Richard Allen, the man convicted in the 2017 killings of two teenage girls who disappeared in Delphi, Indiana, was sentenced Friday to 130 years in prison. Allen was sentenced to 65 years for each ...
The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.